Systemic AL amyloidosis due to non-Hodgkin's lymphoma: An unusual clinicopathologic association

British Journal of Haematology

Volumn 124, Issue 3, 2004, Pages 309-314

  Cohen, A D ^a   Zhou, P ^a   Xiao, Q ^a   Fleisher, M ^a   Kalakonda, N ^a   Akhurst, T ^a   Chitale, D A ^a   Moscowitz, C ^a   Dhodapkar, M V ^a,b   Teruya Feldstein, J ^a   Filippa, D ^a   Comenzo, R L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Amyloidosis; Immunoglobulin light chains; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; IMMUNOGLOBULIN LIGHT CHAIN; RITUXIMAB; SYNDECAN 1;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHOID CELL; MALE; NONHODGKIN LYMPHOMA; PLASMA CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

AGED; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 10744226929     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04779.x     Document Type: Article

References (27)

1. Abraham, R.S., Geyer, S.M., Price-Troska, T.L., Allmer, C., Kyle, R.A., Gertz, M. A. & Fonseca, R. (2003) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated (AL) amyloidosis. Blood, 101, 3801-3807.
2. Armitage, J.O. & Weisenburger, D.D. (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Journal of Clinical Oncology, 15, 2780-2795.
3. Caulet, S., Robert, I., Bardaxoglou, E., Noret, P., Tas, P., Le Prise, Y., Launois, B. & Ramee, M.P. (1995) Malignant lymphoma of mucosa-associated lymphoid tissue: a new etiology of amyloidosis. Pathology, Research and Practice, 191, 1203-1207.
4. Comenzo, R.L. (2000) Hematopoietic cell transplantation for primary systemic amyloidosis: what have we learned. Leukemia and Lymphoma, 37, 245-258.
5. Comenzo, R.L. & Gertz, M.A. (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99, 4276-4282.
6. Comenzo, R.L., Vosburgh, E., Falk, R.H., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L.M., Berk, J.L., Akpek, G., LaValley, M., O'Hara, C., Arkin, C.F., Wright, D.G. & Skinner, M. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis; survival and responses in 25 patients. Blood, 91, 3662-3670.
7. L germ line gene use and clonal plasma cell burden. Blood, 98, 714-720.
8. Dhodapkar, M.V., Jagannath, S., Vesole, D., Munshi, N., Naucke, S., Tricot, G. & Barlogie, B. (1997) Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leukemia and Lymphoma, 27, 351-356.
9. Dimopoulos, M.A., Panayiotidis, P., Maulopoulos, L.A., Sfikakis, P. & Dalakas, M. (2000) Waldenstrom's macroglobulinemia: clinical features, complications, and management. Journal of Clinical Oncology, 18, 214-226.
10. Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J. & Anagnostopoulos, N. (2002) Treatment of Waldenstrom's macroglobulinemia with rituximab. Journal of Clinical Oncology, 20, 2327-2333.
11. Drayson, M., Tang, L.X., Drew, R., Mead, G.P., Carr-Smith, H. & Bradwell, A.R. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood, 97, 2900-2902.
12. Elstrom, R., Liang, G., Baker, G., Nakhoda, K., Vergilio, J., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A. Kim, S., Alavi, A. & Schuster, S.J. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, 3875-3876.
13. Gertz, M.A., Kyle, R.A. & Noel, F. (1993) Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. Journal of Clinical Oncology, 11, 914-920.
14. Iida, S., Rao, P.H., Nallasivam, P., Hibshoosh, H., Butler, M. & Louie, D.C. (1996) The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood, 88, 4110-4117.
15. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (eds) (2001) World Health Organization Classification of Tumors: Pathology and Genetics of the Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
16. Kyle, R.A. & Gertz, M.A. (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology, 32, 45-59.
17. Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Therneau, T.M. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New England Journal of Medicine, 336, 1202-1207.
18. Lachmann, H.J., Gallimore, R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B. & Hawkins, P.N. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 122, 78-84.
19. Lehman, N.L., Horoupian, D.S., Warnke, R.A., Sundram, U.N., Peterson, K. & Harsh, G.R. (2002) Durai marginal zone lymphoma with massive amyloid deposition: rare low-grade primary central nervous system B-cell lymphoma. Journal of Neurology, 96, 368-372.
20. Lim, J.K., Lacy, M.Q., Kurtin, P.J., Kyle, R.A. & Gertz, M.A. (2001) Pulmonary marginal zone lymphoma of MALT type as a cause of localized pulmonary amyloidosis. Journal of Clinical Pathology, 54, 642-646.
21. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. & Levy, R. (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, 2188-2195.
22. Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. & Goldstone, A.H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 13, 588-595.
23. Perfetti, V., Casarini, S., Palladini, G., Colli Vignarelli, M., Klersy, C., Diegoli, M., Ascari, E. & Merlini, G. (2002) Analysis of V-J expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (III) as a new amyloid-associated germline gene segment. Blood, 100, 948-953.
24. Rose, A.L., Smith, B.E. & Maloney, D.G. (2002) Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood, 100, 1765-1773.
25. Sanchorawala, V., Wright, D., Seldin, D., Falk, R., Finn, K., Dember, L., Berk, J., Quillen, K., Anderson, J., Comenzo, R.L. & Skinner, M. High dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation (in press).
26. Simmonds, P.D., Cottrell, B.J., Mead, G.M., Wright, D.H. & Whitehouse, J.M. (1997) Lymphadenopathy due to amyloid deposition in non-Hodgkin's lymphoma. Annals of Oncology, 3, 267-270.
27. Wirth, A., Seymour, J.F., Hicks, R.J., Ware, R., Fisher, R., Prince, M., MacManus, M.P., Ryan, G., Januszewicz, H. & Wolf, M. (2002) Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. American Journal of Medicine, 112, 262-268.